We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Announces Favorable Legal Ruling from European Patent Office
News

Agilent Announces Favorable Legal Ruling from European Patent Office

Agilent Announces Favorable Legal Ruling from European Patent Office
News

Agilent Announces Favorable Legal Ruling from European Patent Office

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Announces Favorable Legal Ruling from European Patent Office"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. has announced a favorable legal ruling from the European Patent Office regarding Agilent’s opposition to patent EP 0853679, assigned to Affymetrix.

On Oct. 21, 2003, Agilent joined Combimatrix and Clonediag in opposing the patent, titled “Expression Monitoring by Hybridization to High Density Oligonucleotide Arrays.”

Agilent opposed the breadth of the patent, particularly the patent’s broad use of the term “control probe” in connection with gene-expression microarrays. Gene-expression microarrays are part of Agilent’s portfolio of products for genetic research.

An opposition hearing was held on Sept. 12, 2006. During the hearing the patent claims were narrowed, but Agilent and Clonediag still believed them to be overbroad and vague.

After the written findings were issued on May 11, 2009, Agilent appealed. An appeal hearing was held July 5, 2012, resulting in this ruling, with all EP 0853679 claims rejected and the patent revoked in totality.

“This ruling is a very positive result for Agilent’s many European gene-expression microarray customers and the entire European gene-expression community,” said Robert Schueren, Agilent vice president, Genomics.

“The ruling allows customers to continue using established workflows and protocols, including control probes, without having to worry about potential patent infringement.”

Advertisement